Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2022-06-09

EMA Authorised: Dasselta (desloratadine) — Krka, d.d., Novo mesto

View source ↗

Summary

Dasselta (desloratadine) by Krka has been authorised for allergic rhinitis (perennial and seasonal) and urticaria in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dasselta (desloratadine)

Snippet

Status: Authorised. Therapeutic area: Rhinitis, Allergic, Perennial;Rhinitis, Allergic, Seasonal;Urticaria. MAH: Krka, d.d., Novo mesto. Decision date: 30/05/2022